The Association of the British Pharmaceutical Industry has issued the following statement in response to the publication of the Government’s Health Bill today.
Director General of the ABPI Dr Richard Barker said:
“The Association of the British Pharmaceutical Industry welcomes the fact that Government is putting patient outcomes at the heart of health policy. Naturally, like other interested parties, we are watching closely to see how the proposed changes – particularly those around structural reform and commissioning – are implemented and their impact on culture, attitudes and relationships within the health community. A key relationship is between the NHS and the life sciences industry, which is a valuable partner to the NHS in achieving better outcomes through innovation - so that the UK rewards and recognises the contribution research and development makes to patients as well as to the economy.”
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064 Email: email@example.com
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.